William Hoos

965 total citations
18 papers, 511 citations indexed

About

William Hoos is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, William Hoos has authored 18 papers receiving a total of 511 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 8 papers in Cancer Research and 5 papers in Molecular Biology. Recurrent topics in William Hoos's work include Pancreatic and Hepatic Oncology Research (11 papers), Cancer Genomics and Diagnostics (8 papers) and Advanced Biosensing Techniques and Applications (4 papers). William Hoos is often cited by papers focused on Pancreatic and Hepatic Oncology Research (11 papers), Cancer Genomics and Diagnostics (8 papers) and Advanced Biosensing Techniques and Applications (4 papers). William Hoos collaborates with scholars based in United States, Spain and Palestinian Territory. William Hoos's co-authors include Suresh T. Chari, Ziding Feng, Sajan Jiv Singh Nagpal, Harika Kandlakunta, Gloria M. Petersen, Ayush Sharma, Lola Rahib, Lynn M. Matrisian, Julie Fleshman and Todd Hembrough and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Cancer Research.

In The Last Decade

William Hoos

17 papers receiving 503 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
William Hoos United States 8 388 177 173 129 71 18 511
Alexander Ney United Kingdom 8 302 0.8× 142 0.8× 150 0.9× 102 0.8× 77 1.1× 14 483
Brett Mahon United States 11 142 0.4× 127 0.7× 121 0.7× 78 0.6× 99 1.4× 35 494
Christina Finlayson United States 13 288 0.7× 153 0.9× 303 1.8× 117 0.9× 41 0.6× 29 634
Gerhard Schenkirsch Germany 14 354 0.9× 71 0.4× 103 0.6× 156 1.2× 75 1.1× 44 532
Linda J.W. Bosch Netherlands 16 453 1.2× 286 1.6× 267 1.5× 99 0.8× 30 0.4× 54 834
Cassann Blake United States 5 298 0.8× 81 0.5× 368 2.1× 74 0.6× 57 0.8× 11 757
Keefe Murphy Ireland 10 151 0.4× 147 0.8× 105 0.6× 112 0.9× 32 0.5× 21 579
J. Lindtner Switzerland 11 471 1.2× 223 1.3× 302 1.7× 51 0.4× 57 0.8× 12 679
Yasushi Iida Japan 12 148 0.4× 191 1.1× 136 0.8× 68 0.5× 69 1.0× 31 668
Mei-Hua Tsou Taiwan 7 290 0.7× 175 1.0× 252 1.5× 171 1.3× 86 1.2× 8 595

Countries citing papers authored by William Hoos

Since Specialization
Citations

This map shows the geographic impact of William Hoos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Hoos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Hoos more than expected).

Fields of papers citing papers by William Hoos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William Hoos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Hoos. The network helps show where William Hoos may publish in the future.

Co-authorship network of co-authors of William Hoos

This figure shows the co-authorship network connecting the top 25 collaborators of William Hoos. A scholar is included among the top collaborators of William Hoos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William Hoos. William Hoos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Stuhlmiller, Timothy J., Asher Wasserman, Glenn A. Kramer, et al.. (2023). AI-Augmented Clinical Decision Support in a Patient-Centric Precision Oncology Registry. 1(1). 58–68. 10 indexed citations
2.
Stadler, Guido, Tyler C. Helmann, Xiuli Zhang, et al.. (2022). 184 Discovery, cloning and functional validation of a neoantigen specific patient derived TCR on the berkeley lights platform, with implications in personalized cancer immunotherapy. Regular and Young Investigator Award Abstracts. A196–A196. 2 indexed citations
3.
Herman, Joseph M., Carrie Tompkins Stricker, Sarah Myers, et al.. (2022). Building a learning network to accelerate improvement in pancreas cancer care and outcomes: Canopy Cancer Collective.. Journal of Clinical Oncology. 40(28_suppl). 368–368. 2 indexed citations
4.
Kenner, Barbara, Natalie Abrams, Suresh T. Chari, et al.. (2021). Early Detection of Pancreatic Cancer. Pancreas. 50(7). 916–922. 36 indexed citations
5.
Rahib, Lola, Karen Chen, Allyson J. Ocean, et al.. (2020). Use of a real-world data approach to rapidly generate outcomes data following a case study of a novel treatment combination in pancreatic adenocarcinoma.. Journal of Clinical Oncology. 38(15_suppl). e16735–e16735. 3 indexed citations
6.
Shrager, Jeff, Mark Shapiro, & William Hoos. (2019). Is Cancer Solvable? Towards Efficient and Ethical Biomedical Science. The Journal of Law Medicine & Ethics. 47(3). 362–368. 4 indexed citations
7.
Barkin, Jodie A., William Hoos, Cassadie Moravek, et al.. (2019). Frequency of Appropriate Use of Pancreatic Enzyme Replacement Therapy and Symptomatic Response in Pancreatic Cancer Patients. Pancreas. 48(6). 780–786. 32 indexed citations
8.
Sharma, Ayush, Harika Kandlakunta, Sajan Jiv Singh Nagpal, et al.. (2018). Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes. Gastroenterology. 155(3). 730–739.e3. 224 indexed citations
9.
Isacoff, William H., Howard A. Reber, Rudolph A. Bedford, et al.. (2018). Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis. Targeted Oncology. 13(4). 461–468. 24 indexed citations
10.
Rahib, Lola, Jodie A. Barkin, William Hoos, et al.. (2017). Frequency of Appropriate Use of Pancreatic Enzyme Replacement Therapy (PERT) and Symptomatic Response in Pancreatic Cancer Patients. The American Journal of Gastroenterology. 112. S23–S23. 2 indexed citations
11.
Pishvaian, Michael J., R Joseph Bender, Lynn M. Matrisian, et al.. (2016). A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative. Oncotarget. 8(48). 83446–83456. 49 indexed citations
12.
Pishvaian, Michael J., Jonathan R. Brody, Lynn M. Matrisian, et al.. (2016). Multi-Omic profiling (MoP) for patients (pts) with pancreatic cancer (PDA): Initial results of the Know Your Tumor (KYT) initiative.. Journal of Clinical Oncology. 34(4_suppl). 282–282. 2 indexed citations
13.
Engebretson, Anitra, Jonathan R. Brody, Lola Rahib, et al.. (2016). The Know Your Tumor (KYT) initiative: A national program of multi-omic molecular profiling (MoP) for patients (Pts) with pancreatic cancer (PDA).. Journal of Clinical Oncology. 34(4_suppl). 279–279. 3 indexed citations
14.
Nucíforo, Paolo, Sheeno Thyparambil, Claudia Aura, et al.. (2015). High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti‐HER2 therapy. Molecular Oncology. 10(1). 138–147. 68 indexed citations
15.
16.
Nucíforo, Paolo, Claudia Aura, Sheeno Thyparambil, et al.. (2015). HER2 quantification by mass spectrometry compared to IHC or ISH in predicting clinical benefit from anti-HER2 therapy in HER2-positive breast cancer (BC).. Journal of Clinical Oncology. 33(15_suppl). 605–605. 1 indexed citations
17.
Nucíforo, Paolo, Sheeno Thyparambil, Ana C. Garrido-Castro, et al.. (2014). Correlation of high levels of HER2 measured by multiplex mass spectrometry with increased overall survival in patients treated with anti-HER2-based therapy.. Journal of Clinical Oncology. 32(15_suppl). 649–649. 1 indexed citations
18.
Hoos, William, et al.. (2013). Pancreatic Cancer Clinical Trials and Accrual in the United States. Journal of Clinical Oncology. 31(27). 3432–3438. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alexander Ney Breakdown of academic impact, for papers by Brett Mahon Breakdown of academic impact, for papers by Christina Finlayson Breakdown of academic impact, for papers by Gerhard Schenkirsch Breakdown of academic impact, for papers by Linda J.W. Bosch Breakdown of academic impact, for papers by Cassann Blake Breakdown of academic impact, for papers by Keefe Murphy Breakdown of academic impact, for papers by J. Lindtner Breakdown of academic impact, for papers by Yasushi Iida Breakdown of academic impact, for papers by Mei-Hua Tsou
Rankless by CCL
2026